The severity of diabetic retinopathy is more likely to improve and progression to proliferative diabetic retinopathy is less likely to occur when diabetic macular edema is treated with monthly ranibizumab2
, new research shows. At 36-month follow-up, vision and the severity of diabetic retinopathy were significantly more likely to have improved in patients treated with monthly ranibizumab than in those treated with a sham injection. In addition, ranibizumab-treated patients were approximately 3-fold less likely to develop proliferative diabetic retinopathy than their sham counterparts.
To see more details visit, www.medscape.com